FDA approves TECVAYLI plus DARZALEX FASPRO for relapsed multiple myeloma. Discover what the MajesTEC-3 data means for future immunotherapy strategies.
FDA approves J&J’s teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.
Gilead Sciences’ acquisition of Arcellx signals a strategic shift in CAR T therapy control and scale. Find out what it changes for multiple myeloma.
Starton Therapeutics advances STAR-LLD in Phase 2a. Explore how continuous lenalidomide delivery could reshape multiple myeloma care.
FDA accepts Bristol Myers Squibb’s iberdomide NDA for relapsed multiple myeloma. Find out what this CELMoD filing could change next.
Find out how DARZALEX FASPRO’s FDA approval for transplant-ineligible myeloma patients could shift frontline treatment standards.
TECVAYLI outperformed standard regimens in relapsed/refractory myeloma. Find out what the Phase 3 MajesTEC-9 trial means for future treatment lines.
Vyriad secures $85M to launch VV169, its in vivo CAR T therapy for multiple myeloma. Find out how this platform could reshape cancer immunotherapy.
Johnson & Johnson’s CARVYKTI shows 80 percent treatment-free survival at 30 months in second-line myeloma. Is CAR-T moving to earlier use?